Scott Mitchell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Scott Mitchell has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Harm van Essen
Eindhoven University of Technology, Eindhoven, Netherlands
3 shared publications - Laurene Vaughan
RMIT University, Melbourne, Australia
3 shared publications - Liam Fennessy
RMIT University, Melbourne, Australia
3 shared publications - Regina Bernhaupt
Eindhoven University of Technology, Eindhoven, Netherlands
3 shared publications - Yaxin Zheng
Eindhoven University of Technology, Eindhoven, Netherlands
3 shared publications Gundula Min-Oo
Gilead Sciences, Foster City, CA
1 shared publication
Latest Publications
- Open Access
- 15 November 2026
- Published by Association for Computing Machinery (ACM)
- p. 585-587
Making Agency Designable: An Engagement Framework for Domestic Digital Twins
- 15 November 2026
- Published by Association for Computing Machinery (ACM)
- p. 585-587
Open AccessMaking Agency Designable: An Engagement Framework for Domestic Digital Twins
- 2 July 2026
- Published by Springer Nature
- p. 104-118
A Conceptual Framework for Designing Temporal Interactions with Digital Twin-Enabled Systems
- 2 July 2026
- Published by Springer Nature
- p. 104-118
A Conceptual Framework for Designing Temporal Interactions with Digital Twin-Enabled Systems
- 9 September 2025
- Published by Springer Nature
- p. 477-498
Design of Temporal Interfaces of Digital Twins in Domestic Energy Consumption
- 9 September 2025
- Published by Springer Nature
- p. 477-498
Design of Temporal Interfaces of Digital Twins in Domestic Energy Consumption
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 3517
Abstract 3517: Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity
Hematopoietic progenitor kinase 1 (HPK1, mitogen-activated kinase kinase kinase kinase 1 [MAP4K1]), a cytosolic STE20 ser/thr kinase from the germinal center family of kinases, regulates the function of diverse immune populations including T cells, B cells, and dendritic cells. In T cells, activated HPK1 regulates T cell receptor (TCR) signaling by phosphorylating the adaptor protein SLP76 on Ser376, which induces the association of SLP76 with 14-3-3 proteins. This SLP76/14-3-3 complex leads to its disassociation from the TCR signalosome, resulting in reduced downstream TCR signaling. The kinase activity of HPK1 is necessary for its regulatory function as mice expressing a mutant kinase-inactive HPK1 demonstrate enhanced T cell activity and superior tumor growth control compared to their WT counterparts. Here we describe a highly potent, selective and orally bioavailable small molecule inhibitor of HPK1 which displays sub-nanomolar HPK1 inhibition, good selectivity against MAP4K family members and oral bioavailability in preclinical animal models. Pharmacological inhibition of HPK1 kinase activity with Gilead’s HPK1 inhibitor compound demonstrates robust inhibition of pSLP76 S376 with concomitant enhancement in T cell activation, proliferation and effector function in in vitro assays. These immune enhancing effects translate into in vivo preclinical tumor models, where treatment with Gilead’s HPK1 inhibitor compound results in heightened T cell activation and effector function and enhanced tumor growth control both as a single agent and in combination with PD-1 blockade. In summary, our data show that Gilead’s HPK1 inhibitor compound is expected to be a selective, orally bioavailable HPK1 inhibitor with potential to combine with checkpoint inhibitors and other immuno-oncology agents. Citation Format: Jacob S. Lee, Pamela Toy, Gundula Min-Oo, Tony Lee, Patrick Salvo, JeanPhilippe Belzile, Sheila Clancy, Jonathan Nazareno, Mengshu Xu, Weimei Xing, Marilyn Giacomini, Rex Santos, Lance Stapleton, Adele Wang, Vladislava Juric, Scott A. Mitchell, Michelle Kuhne. Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3517.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 3517
Open AccessAbstract 3517: Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity
Hematopoietic progenitor kinase 1 (HPK1, mitogen-activated kinase kinase kinase kinase 1 [MAP4K1]), a cytosolic STE20 ser/thr kinase from the germinal center family of kinases, regulates the function of diverse immune populations including T cells, B cells, and dendritic cells. In T cells, activated HPK1 regulates T cell receptor (TCR) signaling by phosphorylating the adaptor protein SLP76 on Ser376, which induces the association of SLP76 with 14-3-3 proteins. This SLP76/14-3-3 complex leads to its disassociation from the TCR signalosome, resulting in reduced downstream TCR signaling. The kinase activity of HPK1 is necessary for its regulatory function as mice expressing a mutant kinase-inactive HPK1 demonstrate enhanced T cell activity and superior tumor growth control compared to their WT counterparts. Here we describe a highly potent, selective and orally bioavailable small molecule inhibitor of HPK1 which displays sub-nanomolar HPK1 inhibition, good selectivity against MAP4K family members and oral bioavailability in preclinical animal models. Pharmacological inhibition of HPK1 kinase activity with Gilead’s HPK1 inhibitor compound demonstrates robust inhibition of pSLP76 S376 with concomitant enhancement in T cell activation, proliferation and effector function in in vitro assays. These immune enhancing effects translate into in vivo preclinical tumor models, where treatment with Gilead’s HPK1 inhibitor compound results in heightened T cell activation and effector function and enhanced tumor growth control both as a single agent and in combination with PD-1 blockade. In summary, our data show that Gilead’s HPK1 inhibitor compound is expected to be a selective, orally bioavailable HPK1 inhibitor with potential to combine with checkpoint inhibitors and other immuno-oncology agents. Citation Format: Jacob S. Lee, Pamela Toy, Gundula Min-Oo, Tony Lee, Patrick Salvo, JeanPhilippe Belzile, Sheila Clancy, Jonathan Nazareno, Mengshu Xu, Weimei Xing, Marilyn Giacomini, Rex Santos, Lance Stapleton, Adele Wang, Vladislava Juric, Scott A. Mitchell, Michelle Kuhne. Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3517.
- 2 January 2018
- Published by Taylor & Francis in Third Text
- Vol. 32 (1) , 55-67
Narratives of Resistance and Repair in Consumer Society
This article explores consumer practices of repair and reuse via a series of stories; the making of an iPod case, the sharing of Apple repair manuals, the development of a GI Joe computer game, the animation of a robotic dog, and the repair of a laptop computer. Together, these stories reveal how the space of consumption is shaped by a complex combination of physical design, software protection measures, restricted technical documentation and intellectual property laws. Within this highly controlled environment consumers are forced to adopt a tactical approach as they take up the products of mass-production and remake them to match their own desires. In forging unauthorised paths through the consumer environment, practices of repair and reuse challenge established notions of ‘proper’ use and reveal the commercial forces that shape consumption.
- 2 January 2018
- Published by Taylor & Francis in Third Text
- Vol. 32 (1) , 55-67
Narratives of Resistance and Repair in Consumer Society
This article explores consumer practices of repair and reuse via a series of stories; the making of an iPod case, the sharing of Apple repair manuals, the development of a GI Joe computer game, the animation of a robotic dog, and the repair of a laptop computer. Together, these stories reveal how the space of consumption is shaped by a complex combination of physical design, software protection measures, restricted technical documentation and intellectual property laws. Within this highly controlled environment consumers are forced to adopt a tactical approach as they take up the products of mass-production and remake them to match their own desires. In forging unauthorised paths through the consumer environment, practices of repair and reuse challenge established notions of ‘proper’ use and reveal the commercial forces that shape consumption.